email article
Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial showed.
Median overall survival (OS) was about 14 months with cisplatin-containing chemotherapy when paired with either placebo or the angiogenesis inhibitor bevacizumab (Avastin). Progression-free survival (PFS), a secondary endpoint, favored the bevacizumab arm (8.0 vs 6.7 months).
Grade ≥3 adverse events (AEs) occurred in a similar proportion of patients in each arm, although bevacizumab-related toxicities occurred more often with the addition of the angiogenesis inhibitor, reported Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues, in the
New research indicates that certain anti-cancer therapies may hasten cellular aging, where changes in the DNA of patients may contribute to greater inflammation and fatigue. The findings are published by Wiley early online in CANCER, a peer-reviewed journal of the American Cancer Society.